$ARCT
Arcturus Therapeutics Holdings Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023063778 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $33.99M $45.14M
YoY Change -78.8% 237.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.51M $13.40M
YoY Change 5.46% 7.3%
% of Gross Profit
Research & Development $36.62M $51.08M
YoY Change 35.73% 35.53%
% of Gross Profit
Depreciation & Amortization $815.0K $820.0K
YoY Change 47.91% 96.64%
% of Gross Profit
Operating Expenses $49.13M $64.45M
YoY Change 26.48% 28.46%
Operating Profit -$19.31M
YoY Change -47.53%
Interest Expense $6.827M $4.000M
YoY Change -342.95% 159.57%
% of Operating Profit
Other Income/Expense, Net $3.981M
YoY Change -1340.19%
Pretax Income -$8.311M -$15.33M
YoY Change -107.01% -56.53%
Income Tax $262.0K $900.0K
% Of Pretax Income
Net Earnings -$8.573M -$16.22M
YoY Change -107.31% -54.0%
Net Earnings / Revenue -25.22% -35.94%
Basic Earnings Per Share -$0.61
Diluted Earnings Per Share -$0.32 -$0.61
COMMON SHARES
Basic Shares Outstanding 26.72M 26.60M
Diluted Shares Outstanding 26.57K

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $292.0M $311.9M
YoY Change -25.49% 31.23%
Cash & Equivalents $292.0M $311.9M
Short-Term Investments
Other Short-Term Assets $62.52M $43.10M
YoY Change 619.79% 519.25%
Inventory
Prepaid Expenses
Receivables $32.06M $38.22M
Other Receivables $0.00 $0.00
Total Short-Term Assets $386.6M $393.3M
YoY Change -4.15% 59.42%
LONG-TERM ASSETS
Property, Plant & Equipment $12.43M $12.72M
YoY Change 0.1% 12.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.885M $22.10M
YoY Change -9.98% 961.99%
Total Long-Term Assets $42.81M $64.38M
YoY Change -9.02% 37.14%
TOTAL ASSETS
Total Short-Term Assets $386.6M $393.3M
Total Long-Term Assets $42.81M $64.38M
Total Assets $429.4M $457.7M
YoY Change -4.66% 55.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.279M $18.36M
YoY Change -29.13% 2.23%
Accrued Expenses $31.88M $28.55M
YoY Change 5.45% 11.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $81.99M $87.68M
YoY Change -35.43% 15.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $20.00M
YoY Change -37.57%
Other Long-Term Liabilities $497.0K $976.0K
YoY Change -82.28% -73.45%
Total Long-Term Liabilities $497.0K $20.98M
YoY Change -82.28% -41.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $81.99M $87.68M
Total Long-Term Liabilities $497.0K $20.98M
Total Liabilities $150.9M $177.6M
YoY Change -16.21% 20.02%
SHAREHOLDERS EQUITY
Retained Earnings -$367.9M -$356.2M
YoY Change 8.81% -21.8%
Common Stock $27.00K $27.00K
YoY Change 0.0% 3.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $278.5M $280.1M
YoY Change
Total Liabilities & Shareholders Equity $429.4M $457.7M
YoY Change -4.66% 55.86%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$8.573M -$16.22M
YoY Change -107.31% -54.0%
Depreciation, Depletion And Amortization $815.0K $820.0K
YoY Change 47.91% 96.64%
Cash From Operating Activities -$629.0K -$32.41M
YoY Change -100.39% -23.57%
INVESTING ACTIVITIES
Capital Expenditures $875.0K $980.0K
YoY Change -77.02% -144.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$875.0K -$980.0K
YoY Change -77.02% -55.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -18.66M 21.84M
YoY Change 735.89% -1890.16%
NET CHANGE
Cash From Operating Activities -629.0K -32.41M
Cash From Investing Activities -875.0K -980.0K
Cash From Financing Activities -18.66M 21.84M
Net Change In Cash -20.16M -11.55M
YoY Change -113.07% -74.79%
FREE CASH FLOW
Cash From Operating Activities -$629.0K -$32.41M
Capital Expenditures $875.0K $980.0K
Free Cash Flow -$1.504M -$33.39M
YoY Change -100.96% -16.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001768224
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38942
dei Entity Registrant Name
EntityRegistrantName
ARCTURUS THERAPEUTICS HOLDINGS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0595345
dei Entity Address Address Line1
EntityAddressAddressLine1
10628 Science Center Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
900-2660
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ARCT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26723332
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
311918000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
391883000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
35000000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
38220000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2764000
CY2023Q3 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
8130000
CY2022Q4 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
8686000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
393268000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
403333000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12715000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12415000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29534000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32545000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
22133000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2094000
CY2023Q3 us-gaap Assets
Assets
457650000
CY2022Q4 us-gaap Assets
Assets
450387000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
18362000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7449000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28553000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30232000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
60655000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
40768000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28648000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
87683000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126984000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41911000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
20071000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
20000000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27018000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30216000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
976000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2804000
CY2023Q3 us-gaap Liabilities
Liabilities
177588000
CY2022Q4 us-gaap Liabilities
Liabilities
180075000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26723000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26723000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26555000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26555000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
27000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
636194000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
608426000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356159000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-338141000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
280062000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270312000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
457650000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
450387000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45140000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13369000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
135944000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45706000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51077000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37688000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155513000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
120770000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13377000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12488000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40364000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34211000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
64454000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
50176000
us-gaap Operating Expenses
OperatingExpenses
195877000
us-gaap Operating Expenses
OperatingExpenses
154981000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19314000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-36807000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59933000
us-gaap Operating Income Loss
OperatingIncomeLoss
-109275000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-515000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1862000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-175000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3237000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
33953000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3981000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-321000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9710000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1445000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15329000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35266000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16445000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-107998000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
893000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1573000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16222000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35266000
us-gaap Net Income Loss
NetIncomeLoss
-18018000
us-gaap Net Income Loss
NetIncomeLoss
-107998000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.09
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26574
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26574
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26467
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26467
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26559
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26559
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26423
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26423
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16222000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35266000
us-gaap Net Income Loss
NetIncomeLoss
-18018000
us-gaap Net Income Loss
NetIncomeLoss
-107998000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16222000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35266000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18018000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-107998000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270312000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
50754000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8182000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
329248000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-52550000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8383000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
94000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
285175000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16222000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9269000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1231000
CY2023Q3 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
609000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
280062000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
228211000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-51169000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7371000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
336000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
184749000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21563000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7274000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
170717000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35266000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9436000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
369000
CY2022Q3 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
411000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
145667000
us-gaap Net Income Loss
NetIncomeLoss
-18018000
us-gaap Net Income Loss
NetIncomeLoss
-107998000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2142000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
976000
us-gaap Share Based Compensation
ShareBasedCompensation
25834000
us-gaap Share Based Compensation
ShareBasedCompensation
24081000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-515000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-90000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
2976000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
33953000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-502000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5084000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
35456000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1323000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-556000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1858000
arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-3011000
arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-2290000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10497000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5335000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3437000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2015000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
33960000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-53578000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3198000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3475000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17470000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-128266000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2026000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3919000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2026000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3919000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
20000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1325000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
962000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
609000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
411000
us-gaap Repayments Of Debt
RepaymentsOfDebt
27364000
us-gaap Repayments Of Debt
RepaymentsOfDebt
2000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5430000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-627000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24926000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-132812000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393977000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372569000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
369051000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239757000
us-gaap Interest Paid Net
InterestPaidNet
2102000
us-gaap Interest Paid Net
InterestPaidNet
585000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
30191000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
416000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2761000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356200000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-338100000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
369100000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
22133000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
311918000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
237676000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
35000000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2081000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
369051000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239757000
us-gaap Dividends
Dividends
0
us-gaap Dividends
Dividends
0
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2764000
arct Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
170244000
arct Contract With Customer Asset Deductions
ContractWithCustomerAssetDeductions
-134788000
CY2023Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
38220000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
48719000
arct Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
169904000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-135944000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
82679000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3884000
CY2023Q3 arct Clinical Accruals Current
ClinicalAccrualsCurrent
3180000
CY2022Q4 arct Clinical Accruals Current
ClinicalAccrualsCurrent
4531000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20640000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18198000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7925000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5783000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12715000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12415000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2100000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10200000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4038000
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
482000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1295000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4200000
CY2023Q3 us-gaap Contractual Obligation
ContractualObligation
3492000
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
7468000
CY2023Q3 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
6999000
CY2022Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
9016000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28553000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30232000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
800000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
700000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9269000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9436000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25834000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24081000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1378000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5646000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4019000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3603000
CY2023Q3 arct Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
23283000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
37929000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6711000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
31218000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.049
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1400000
us-gaap Operating Lease Cost
OperatingLeaseCost
4200000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1400000
us-gaap Operating Lease Cost
OperatingLeaseCost
3300000

Files In Submission

Name View Source Status
0000950170-23-063778-index-headers.html Edgar Link pending
0000950170-23-063778-index.html Edgar Link pending
0000950170-23-063778.txt Edgar Link pending
0000950170-23-063778-xbrl.zip Edgar Link pending
arct-20230930.htm Edgar Link pending
arct-20230930.xsd Edgar Link pending
arct-ex10_31.htm Edgar Link pending
arct-ex10_32.htm Edgar Link pending
arct-ex31_1.htm Edgar Link pending
arct-ex31_2.htm Edgar Link pending
arct-ex32_1.htm Edgar Link pending
arct-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img266243248_0.jpg Edgar Link pending
img266243248_1.jpg Edgar Link pending
img266243248_2.jpg Edgar Link pending
img266243248_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
arct-20230930_pre.xml Edgar Link unprocessable
arct-20230930_cal.xml Edgar Link unprocessable
arct-20230930_lab.xml Edgar Link unprocessable
arct-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
arct-20230930_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending